Investment Q&A

Q: With declines from highs; is 5i/i2i actively increasing it's position in this stock? I have a small position in my us tfsa, looking to increase with a 3 to 5 year hold. In the medical genetics field, is there something about NVTA product lineup that gives it an edge over competitors?

Q: Do you know management's financial predictions for the upcoming quarter? I believe the numbers are to be released next Tuesday August 3rd. I'm a shareholder and am in a minor loss position. I need to take more money out my RIF but thinking of waiting until after the release of numbers before deciding wether to sell or hold NVTA. I prefer companies with sterling managers and missing 8 quarters is disconcerting. Any thoughts you have would be appreciated.
Jim

Q: How do you feel about investing in NVTA right now? Do you agree that their annual compound growth in revenue from 2017 to 2020 at 42% will translate into a higher price in the next few years? What would concern you about NVTA.... balance sheet? Thanks!

Q: What is your long term outlook on the above companies.

I own them and some ARKG. Do you have any others you fell would complement them? I got space to add another name or two with out being overweight in the sector.

Q: As I watch the growth stocks in my portfolio get crushed I can't help but also feel excited at the buying opportunities that are being created for others I thought I had missed. With the Nasdaq only 1200 points off its high and companies like TWST (down 57%), LMND (down to 60%) or BOMN (down 50%) or NVTA (down 55%) it is undeniable that many of these stocks have been revalued.

My question pertains both to these specific companies and smaller caps in general. Do you think companies like these are close to finding a floor meaning that it is time to start buying in tranches as they inch down or do you consider it more likely that we need a major sell off and full capitulation?

With these specific companies, what would be an entry price that makes sense for each for the first 1/2 and then a full position. (ie buy a 1/2 of LMND at 75 and then full at 60 if it gets there).

Q: Hi team,

Grateful for your views on Oncorus (oncr-a). Apparently, the CEO was previously head of oncology at Moderna. Any other favorites for growth in the field of immunotherapy ?

With great appreciation for your work,

Jacques IDS

Q: Hi 5i Team. Thanks as always. I'm looking to start some positions in the USD side of my TFSA over the course of the next month or so. I'm particularly interested in good growth opportunities in the following sectors: Technology, Healthcare, Industrials and Communications. Can you suggest a few US stocks within each of these sectors that are some of your best ideas right now? I am open to all types of suggestions, but already having a few larger caps (MFST, ABBV, LMT) I would prefer small or mid-cap suggestions where possible. Please take as many credits as necessary - thanks again.

Q: Hello 5i Team
I have read the Q/A on many of these stock already , but due to the current market correction and the stock rotation .How would you rate these stocks today and would you sell any of them .Is there futher down side risk on these stocks .What would you recommend ? Please deduct credits as you feel appropriate .
Thanks for you continous service and excellent ongoing advice.

Q: What is their balance sheet, would you buy them today and in what order?

Thanks,
Milan

Q: I see ABCL is taking it on the chin today down 12% as I type this question. Since about January 1, 2021 I have been considering selling my NVTA and putting the money in ABCL but have done nothing to date. (Procrastination is sometimes the key to success)! NVTA weighting is 1.5%. 2 Questions...
Do you think ABCL has better long term prospects than NVTA and would you be interested in ABCL at +/- $31.50 USD? Or do you think I should use the basket approach and hold both?
Thanks,
Jim

Q: What would be your top pick today among these four biotech stocks ?

Q: Peter; What would be an example/s of “ Innovation” companies? Thanks. Rod

Q: Hi Team,
I'd like to start positions in an aggressive growth portfolio in the artificial intelligence, genomics, renewable energy (and EV) sectors (2-3 positions per sector). Holding time 2-5 years.
Also considering Bionano Genomics (BNGO).
1. Please rank the sectors for expected growth. Are there any others I should consider? Are they already overbought/overpriced?
2. Please rank the stocks in each sector for expected growth. Are there any others I should consider?
Thanks!

Q: HI 5i Team. I really appreciate your comments that speak to opportunities/areas or perhaps "themes" where you currently see good growth opportunities now and in the coming years. Some commentators have pointed to themes such as EV and materials that support EV, clean tech generally, changes in healthcare, etc. What would you consider to be some of the better investing themes right now (say 3 or 4?) and what would some of your suggestions right now for some good Canadian and good US stock selections within each, with growth in mind over a roughly 5 year horizon in a TFSA. I already have positions in LSPD, WELL, XBC and QST, and I plan to acquire AZT next. So I would be interested in hearing about your ideas and suggestions that might provide some additional diversification into other areas. Thanks very much - take as many question credits as necessary.

Q: I currently own some ARKG and CRSP. If you were to buy a few more individual stocks in this space and had a long term time frame and high risk tolerance what would you buy?

Q: In your answer to a question recently asked on Genomics, your suggestion was to buy an ETF such as ARKG or EAGB. You also mentioned that if so inclined you could start adding small amounts in specific stocks which of course be riskier. Would you be able to suggest 3 or 4 of these stocks either US or Canadian, preferably at least one of each.

Q: Can you please provide an update on Invitae. They guided lower today and stock slipped 10%.
How would you rate this company, and would you buy more on the dip.?

Q: Peter and Team:
I need some exposure to the healthcare sector and my choices are very limited in Canada, especially when Johnathon doesn't want to play in the Chess Game presently. What are your favourite US names, and where does ABBVIE fit in to the puzzle? When I am typing a question, does it time out after so many minutes?
Regards,
Ben.

Q: Between NVTA, CRSP, EXAS which one will prefer to start a new position - from a quality of product and pipeline - runway and performance perspective. Thanks

Q: Hi guys. Would you be able to tell me your ratings on these medical stocks for growth and risk please. It would be a 3 year time frame minimum. Thks again for the great job you do.